By Dr Carole Abigail Harris

Journal articles

Reis H; Al-Ahmadie H; Gaisa NT; Lopez-Beltran A; Maclean F; Tsuzuki T; Werneck Da Cunha I; Amin MB; Aning J; Aron M; Athanazio D; Bambury RM; Cheng L; Gopalan A; Gulmann C; Guo CC; Harris C; Iyer G; Jimenez RE; Jinzaki M; Kikuchi E; Lal P; Miyai K; Netto GJ; Pan CC; Panebianco V; Van Rhijn BWG; Siefker-Radtke A; Smith SC; Szarvas T; Wobker SE; Kristiansen G; Paner GP; Ferran A; Ciara B; Simone B; Bezerra Stephania M; Ruth B; Preeti C; Mee CY; Alessia C; Downes MR; Nadine E; Achim F; Aiman H; Ann HL; Arndt H; Umi H; Loren H; Jiaoti H; Gopa I; Laura J; Seema K; Sarah K; Hojung L; Katia L; Nick M; Christina M; Teresa M; Rodolfo M; Marie O; Soon PY; Maria P; Francesca S; Nigam S; John S; Guido S; Sueli S; Nicole S; Matthew T; Maria T; Isabel T; Funda VL; Van Leenders G; Ljiljana V; Gang W; Daniela W; Wightman RH; Williamson SR; Huihui Y; Hong Z, 2025, 'The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms', American Journal of Surgical Pathology, http://dx.doi.org/10.1097/PAS.0000000000002416

Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C, 2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67, http://dx.doi.org/10.1111/bju.16190

Pook DW; Harris CA; Link E; Goh JC; Parnis F; Gurney H; Kichenadasse G; Underhill C; Torres J; Roncolato F; Inderjeeth AJ; Conduit C; McJannett MM; Davis ID; Gedye C, 2024, 'UNICAB: Cabozantinib in locally advanced or metastatic non‐clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802).', Journal of Clinical Oncology, 42, pp. 428 - 428, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.428

Caperchione CM; English M; Sharp P; Agar MR; Phillips JL; Liauw W; Harris CA; McCullough S; Lilian R, 2023, 'Exploring the practicality and acceptability a brief exercise communication and clinician referral pathway in cancer care: a feasibility study', BMC Health Services Research, 23, http://dx.doi.org/10.1186/s12913-023-10003-x

Gurney H; Clay TD; Oliveira N; Wong S; Tran B; Harris C, 2023, 'Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia', Asia Pacific Journal of Clinical Oncology, 19, pp. 585 - 595, http://dx.doi.org/10.1111/ajco.14001

Albiges L; Beckermann K; Miller WH; Goh JC; Gajate P; Harris CA; Suárez C; Peer A; Park SH; Stadler WM; Weickhardt AJ; Faust G; Fong PCC; Waddell T; Venugopal B; Yin L; Wang D; Perini RF; Powles T, 2023, 'Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.', Journal of Clinical Oncology, 41, pp. 4553 - 4553, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4553

Gedye C; Harris CA; Stockler MR; Morris M; Ferguson T; Goh JCH; Martin A; Underhill CR; Pook D; Krieger LEM; Kichenadasse G; Joshi AJ; Subramaniam S; Zebic DS; Zhang A; Joshua AM; Toner GC; Vasey PA; Prithviraj P; Davis ID, 2023, 'Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)', ANNALS OF ONCOLOGY, 34, pp. S1014 - S1014, http://dx.doi.org/10.1016/j.annonc.2023.09.1116

Caperchione CM; Stolp S; Phillips JL; Agar M; Sharp P; Liauw W; Harris CA; McCullough S; Lilian R, 2022, 'Cancer survivors’ exercise beliefs, knowledge, and behaviors: An Australian National Survey', Asia Pacific Journal of Clinical Oncology, 18, pp. 625 - 633, http://dx.doi.org/10.1111/ajco.13729

Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK; Ferguson TR; Lin TP; Chevreau C; Burke JM; Doshi G; Melichar B; Topart D; Oudard S; Kopyltsov E; Hammers HJ; Alva A; Menezes JDJ; Silva AGE; Winquist EW; Hamzaj A; Procopio G; Karaszewska B; Nowakowska-Zajdel EM; Alekseev BY; Gafanov RA; Izmailov A; Semenov A; Afanasyev SG; Lipatov ON; Srinivas S; McDermott D; Kochuparambil ST; Davis ID; Peltola K; Sabbatini R; Chung J; Shkolnik MI; Matveev VB; Gajate Borau P; McCune S; Hutson TE; Dri A; Sales SC; Yeung C; Alcala Castro CM; Bostrom P; Laguerre B; Buttigliero C; de Giorgi U; Fomin EA; Zakharia Y; Hwang C; Singer EA; Yorio JT; Waterhouse D; Kowalyszyn RD; Alfie MS; Yanez Ruiz E; Buchler T; Kankaanranta K; Ferretti G; Kimura G; Nishimura K; Masumori N; Tamada S; Kato H; Kitamura H; Danielewicz I; Wojcik-Tomaszewska J; Sala Gonzalez N; Chiu KY; Atkins MB; Heath E; Rojas-Uribe GA; Gonzalez Fernandez ME; Feyerabend S; Pignata S; Numakura K; Cybulska Stopa B, 2022, 'Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial', Lancet Oncology, 23, pp. 1133 - 1144, http://dx.doi.org/10.1016/S1470-2045(22)00487-9

Caperchione CM; Sharp P; Phillips JL; Agar M; Liauw W; Harris CA; Marin E; McCullough S; Lilian R, 2022, 'Bridging the gap between attitudes and action: A qualitative exploration of clinician and exercise professional's perceptions to increase opportunities for exercise counselling and referral in cancer care', Patient Education and Counseling, 105, pp. 2489 - 2496, http://dx.doi.org/10.1016/j.pec.2021.11.002

Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H, 2022, 'Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review', Immunotherapy, 14, pp. 511 - 520, http://dx.doi.org/10.2217/imt-2021-0225

Kasherman L; Siu DHW; Woodford R; Harris CA, 2022, 'Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future', Cancers, 14, http://dx.doi.org/10.3390/cancers14061406

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2022, 'Corrigendum to “Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy” [Gait Posture 89 (2021) 178–185](S0966636221002514)(10.1016/j.gaitpost.2021.07.010)', Gait and Posture, 92, pp. 1, http://dx.doi.org/10.1016/j.gaitpost.2021.11.006

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2021, 'Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy', Gait and Posture, 89, pp. 178 - 185, http://dx.doi.org/10.1016/j.gaitpost.2021.07.010

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Link E; Davis ID, 2021, 'Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4565

Gedye C; Joshi AJ; Zhang AY; Martin AJ; Joshua AM; Harris CA; Underhill C; Pook DW; Toner GC; Kichenadasse G; So JY; Goh JC; Morris MF; Lawrence NJ; Ferguson T; Vasey PA; Prithviraj P; Subramaniam S; Stockler MR; Davis ID, 2021, 'Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS367

Agar M; Caperchione C; Harris C; Liauw W; Lillian R; McCullough S; Phillips J; Sharp P, 2021, 'Bridging the gap between attitudes and action: Opportunities for the cancer care workforce to support exercise counselling and referral', Journal of Science and Medicine in Sport, 24, pp. S13 - S13, http://dx.doi.org/10.1016/j.jsams.2021.09.042

Siu HW; O'Neill R; Tong M; Hong J; Harris CA; Aghmesheh M; Soudy H, 2020, 'IMMUNE CHECKPOINT INHIBITOR INDUCED OVERLAPPING CARDIAC AND NEUROMUSCULAR TOXICITIES: HIGHLIGHT OF EARLY DIAGNOSIS, EARLY INITIATION OF IMMUNOSUPPRESSIVE THERAPY AND MULTIDISCIPLINARY MANAGEMENT', JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8, pp. A178 - A179, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0292

Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L, 2019, 'Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options', Asia Pacific Journal of Clinical Oncology, 15, pp. 3 - 10, http://dx.doi.org/10.1111/ajco.13289

Harris CA; Daniels BJ; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2 positive early breast cancer patients (2008-2012)', Public Health Research and Practice, 27, http://dx.doi.org/10.17061/phrp2751744

Adelstein BA; Dobbins TA; Harris CA; Marschner IC; Ward RL, 2011, 'A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer', European Journal of Cancer, 47, pp. 1343 - 1354, http://dx.doi.org/10.1016/j.ejca.2011.03.031

Harris CA; Ward RL; Dobbins TA; Drew A; Pearson S, 2011, 'The efficacy of HER2-targeted agents in metastatic breast cancer: A meta-analysis', Annals of Oncology, 22, pp. 1308 - 1317, http://dx.doi.org/10.1093/annonc/mdq593

Goldstein D; Harris C; Harris C, 2010, 'Tamoxifen use in retroperitoneal fibrosis, case report and review of the literature', Internal Medicine Journal, 40, pp. e5 - e7

Back to profile page